Introduction
Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is an autoimmune disorder characterised by psychiatric symptoms, movement disorder and seizures often evolving into a severe encephalopathy. 1 It is characterised by the presence of IgG autoantibodies against the NMDAR in CSF and/or serum and predominantly affects young women. 1 Despite marked neurological disturbance, only 35-50% of patients have abnormal neuroimaging and the course of the disease is typically monophasic. 2 An overlap has recently been recognised between anti-NMDAR encephalitis and inflammatory demyelinating disorders, particularly neuromyelitis optical spectrum disorder (NMOSD). 3 We describe two patients with an initial presentation consistent with anti-NMDAR encephalitis who have subsequently developed relapsing-remitting multiple sclerosis (MS). The cases described build on the three existing reports of anti-NMDAR encephalitis occurring in patients with established MS. [4] [5] [6] These cases outline patients with relapsing-remitting MS who had developed encephalopathy. In two of the previously reported cases, a prompt diagnosis was crucial to commence appropriate immunotherapy and to avoid neuro-psychiatric deficits. In the other reported case, a retrospective diagnosis of NMDAR encephalitis (on saved CSF samples) was made six years after a female patient diagnosed with relapsing-remitting MS had presented with severe cognitive impairment; despite stabilisation of her condition with immunotherapy, she required admission to a nursing home two years after her initial presentation.
Another recent case reported the incidental finding of anti-NMDAR antibodies in a patient with MS. Despite careful evaluation, he did not demonstrate any features of NMDAR encephalitis but was still treated with rituximab. 7 In contrast to MS, anti-NMDAR encephalitis may overlap much more frequently with NMOSD. 2 In a recent large series of 691 patients with anti-NMDAR encephalitis, 3.3% had clinical and/or imaging evidence of a demyelinating disorder, usually with features suggestive of NMOSD (longitudinally-extensive transverse myelitis, bilateral optic neuritis) and most (18 out of 23) had anti-AQP4 or anti-MOG antibodies. 3 In half of cases the demyelinating events were concurrent with the anti-NMDAR encephalitis and half were disseminated in time. 3 An unanswered question is whether the overlap between anti-NMDAR encephalitis and the idiopathic inflammatory demyelinating disorders represents a chance occurrence or whether they may be mechanistically linked. The reported frequency of NMOSD in patients with anti-NMDAR encephalitis in the series described above would argue against chance alone, although, any association is in part clouded by the high rate of co-morbid autoimmune disorders in patients with NMOSD. Another possibility is that inflammatory demyelination may trigger anti-NMDAR encephalitis.
Recently, anti-NMDAR encephalitis has been identified as a major cause of relapsing neurologic symptoms in patients with herpes simplex virus encephalitis (HSE), after excluding inadequately treated infection. 8 The mechanism by which HSE might give rise to parainfectious anti-NMDAR encephalitis is uncertain, but neuronal infection and inflammation might expose antigens that generate an autoimmune response. Whether inflammatory demyelination might also trigger anti-NMDAR encephalitis by a similar mechanism is unclear.
Based on the small number of reports to date, anti-NMDAR encephalitis does not appear to commonly overlap with MS. In the largest study to date investigating the prevalence of anti-NMDAR antibodies in patients with established MS, only 1 of 89 patients tested was positive and that patient had a history of typical anti-NMDAR encephalitis that developed 3 years after the diagnosis of relapsing-remitting MS 5 .
However our two cases, in conjunction with other reports, suggest that there is a degree of overlap between anti-NMDAR encephalitis and MS that is attributable to more than chance.
Encephalopathic relapses, psychosis, severe cognitive impairment and unusual movement disorders have all been described people with MS. In settings where patients with MS develop unusual symptomatology, testing for anti-NMDAR antibodies should be considered in order to guide the most appropriate immunotherapy.
